Start of New EU Research Project Hippocrates: Promoting Early Identification and Improving Outcomes for Patients with Psoriatic Arthritis

Eurice joined a new European research consortium to develop innovative personalised treatment options for people living with this autoimmune disorder most commonly affecting the skin and joints.

By looking into the disease mechanisms of psoriatic arthritis, the 26 partners collaborating in the new research project HIPPOCRATES aim at improving diagnostic and therapeutic options for patients living with this condition. Through gaining a better understanding of the complex interplay between clinical and environmental factors, genotype and molecular pathways, the team aims to enable earlier diagnosis and a more accurate prediction of disease progression. This will revolutionise treatment and deliver profound patient benefits. The project will run for a period of five years with a total budget of EUR 21 million provided by the Innovative Medicines Initiative (IMI 2 JU), a joint undertaking of the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

“HIPPOCRATES represents one further addition to the Eurice-IMI project portfolio in the area of inflammatory diseases (BIOMAP, ImmUniverse, 3TR). All projects focus on identifying biomarkers to improve diagnosis, disease control and therapy response, and thus aim to enable more personalised treatments”, says Dr Vera Schneider, Senior Research and Innovation Manager at Eurice.

The Eurice team contributes to the successful implementation through its long-standing expertise and competences in project and innovation management. Jörg Scherer, Managing Director of Eurice, further notes: “We are eager to face the challenge of developing innovative concepts and plans for the wider outreach and sustainable use of the key results for this very large and ambitious European R&I project”.

Further information: https://hippocrates-imi.eu/